推荐应用
B7-1/CD80 and B7-2/CD86, together with their receptors CD28 and CTLA-4, constitute one of the dominant co-stimulatory pathways that regulate T- and B-cell responses. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20-100 fold higher affinity than CD28 and is involved in the down-regulation of the immune response. Mature human B7-1 consists of a 208 amino acid (aa) extracellular domain (ECD) with two immunoglobulin-like domains, a 21 aa transmembrane domain, and a 25 aa cytoplasmic domain. Within the ECD, human B7-1 shares 50% aa sequence identity with mouse B7-1. Alternative splicing generates a 30 kDa soluble isoform that lacks the transmembrane segment and retains the ability to bind CD28 and CTLA-4 and an isoform that lacks the second Ig-like domain and the transmembrane segment (8). Both human and mouse B7-1 and B7-2 can bind to either human or mouse CD28 and CTLA-4. B7-1 is expressed on activated B cells, activated T cells, and macrophages. B7-2 is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells.
高纯度、高活性、低内毒素、高批间一致性


-25 ~ -15℃保存,收到货之后有效期1年。 复溶后, 无菌条件下,-85 ~ -65℃保存,3个月有效期。
【应用方向】BCMA/TNFRSF17:多发性骨髓瘤免疫治疗的核心靶点蛋白
188
2026-08-31
【应用方向】CD20:B细胞恶性肿瘤免疫治疗的核心靶点蛋白
198
2026-08-31
【应用方向】CD19:血液肿瘤免疫治疗的核心靶点蛋白
223
2026-08-31
【文献解读】Science 重磅成果:西湖大学团队攻克共价蛋白药物核心瓶颈,建立通用高通量速效蛋白筛选平台
392
2026-06-25
【技术讲解】信号通路系列 | Wnt/β-catenin信号通路:细胞的“信号转换器”与“命运规划师”
744
2026-04-29
【文献解读】EGFR信号通路的耐药新视角:当EGFR-TKI遇上免疫压力,肿瘤如何“金蝉脱壳”?
546
2026-04-29
【应用方向】免疫检查点核心家族:B7-CD28超家族蛋白
1145
2026-04-21
【应用方向】TIM-3:下一代肿瘤免疫检查点治疗的核心靶点
859
2026-04-21
【应用方向】SIRP家族分子详解与产品选择指南
719
2026-04-21
【应用方向】OX40-OX40L共刺激轴的T细胞存活调控
795
2026-04-21
【应用方向】LILRB家族:髓系细胞免疫检查点的研究前沿与产品解决方案
1049
2026-04-21
【应用方向】LAG-3(CD223):T细胞耗竭调控网络的核心节点
967
2026-04-21
【应用方向】B7-H3(CD276):双重功能免疫检查点的分子特征与科研应用
1569
2026-04-20
【应用方向】HER2靶点蛋白:驱动肿瘤靶向治疗的核心力量
14724
2026-03-02
【技术讲解】细胞因子科学选型--常见问题解答
11327
2026-09-21





